SCHEMBL14815095

SCHEMBL14815095

Cc1cccc(CN2CCN3C[C@@H](NS(=O)(=O)c4cccc(C(F)(F)F)c4)C[C@H]3C2)c1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CCR2 P41597 2/20 0.48
▸ UBE2M P61081 1/20 0.46
▸ DCUN1D1 Q96GG9 1/20 0.46
▸ DRD2 P14416 1/20 0.44
▸ ADRA1D P25100 1/20 0.44
▸ ADRA1A P35348 1/20 0.44
▸ ADRA1B P35368 1/20 0.44
▸ HTR6 P50406 3/20 0.42
▸ HTR1A P08908 1/20 0.41
▸ HTR7 P34969 1/20 0.41
▸ OPRM1 P35372 1/20 0.40
▸ OPRD1 P41143 1/20 0.40
▸ OPRK1 P41145 1/20 0.40
▸ IDH2 P48735 1/20 0.39
▸ TACR1 P25103 1/20 0.39
▸ SIGMAR1 Q99720 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14833369 1.00 CCR2 (0.48) CCR2UBE2MDCUN1D1DRD2ADRA1D
SCHEMBL14833227 0.94 DRD2 (0.45) DRD2ADRA1DADRA1AADRA1BHTR6
SCHEMBL14815157 0.94 DRD2 (0.45) DRD2ADRA1DADRA1AADRA1BHTR6
SCHEMBL14833401 0.90 UBE2M (0.46) CCR2UBE2MDCUN1D1DRD2ADRA1D
SCHEMBL14815089 0.90 UBE2M (0.46) CCR2UBE2MDCUN1D1DRD2ADRA1D
SCHEMBL14833228 0.87 DRD2 (0.42) CCR2DRD2ADRA1DADRA1AADRA1B
SCHEMBL14815110 0.87 DRD2 (0.42) CCR2DRD2ADRA1DADRA1AADRA1B
SCHEMBL14815077 0.82 DRD2 (0.47) DRD2ADRA1DADRA1AADRA1BHTR6
SCHEMBL14833215 0.82 DRD2 (0.47) DRD2ADRA1DADRA1AADRA1BHTR6
SCHEMBL14814590 0.79 DRD2 (0.52) DRD2ADRA1DADRA1AADRA1BHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8669255-B2 Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers ABBVIE INC. (US) 2014-03-11 — — US disclosed
US-20130085142-A1 SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS ABBVIE INC. (US) 2013-04-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085142-A1 SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS CACNA1C, CACNA1E, CACNA1D CCR2 2651/4885UBE2M 4772/4885DCUN1D1 1024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback